Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
---|---|---|---|---|
16123054 | MK-1064 | 1207253-08-4 | ≧98.0% | |
MK-1064 is a potent, selective and orally active Orexin OX2 Receptor Antagonist for p | ||||
178908 | MI-503 | 1857417-13-0 | 98.0% | |
MI-503 is a potent and selective Menin-MLL inhibitor with IC50 of 14.7 nM. It shows p | ||||
178905 | Merestinib (LY2801653) | 1206799-15-6 | 98.0% | |
Merestinib, also known as LY2801653, is a n orally available, small molecule inhibito | ||||
2017824 | Miglustat hydrochloride | 210110-90-0 | 98.0% | |
Miglustat, also known as OGT 918, is a drug developed by Actelion and is used prima | ||||
2017080111 | MK-0812 | 624733-88-6 | 98.0% | |
MK-0812 is a potent and selective CCR2 antagonist. Chemokine (C-C motif) receptor 2 ( | ||||
201708015 | MONASCIN | 21516-68-7 | 98% | |
It is a potent inhibitor of car inogenesis measured against chemical- or UV-initiated | ||||
174161 | Mephenytoin | 50-12-4 | 98% | |
Mephenytoin(CAS 50-12-4) is a hydantoin, used as an anticonvulsant.Mephenytoin(CAS 50 | ||||
703301 | MT-DADMe-ImmA | 653592-04-2 | 98% by HNMR/HPLC | |
Methylthio-DADMe-immucillin-A (MT-DADMe-ImmA) is an 86-pm inhibitor of human 5-methyl | ||||
17031006 | MI-463 | 1628317-18-9 | 98% | |
MI-463 is a potent inhibitor of Menin-MLL interaction with an IC50 value of 15.3 nM | ||||
17030910 | ML-098 | 878978-76-8 | 98% | |
ML-098, also known as CID-7345532, is an activator of the GTP-binding protein Rab7 (E | ||||
17030804 | ML-265 | 1221186-53-3 | 98% | |
ML265 is a potent PKM2 activator induces tetramerization and reduces tumor formation | ||||
17030717 | MN-64 | 92831-11-3 | 98% | |
MN-64 is a potent and selective inhibitor of Tankyrase 1 and 2 (IC50 = 6 and 72 nM, r | ||||
17030714 | ML241 | 1346528-06-0 | 98% | |
ML241 is a potent and selective inhibitors of p97 ATPase. ML241 inhibit p97 ATPase wi | ||||
17030712 | ML348 | 899713-86-1 | 98% | |
ML348, also known as CID 3238952; SID 160654487, is a reversible LYPLA1 inhibitor wit | ||||
17030612 | Mavoglurant | 543906-09-8 | 98% | |
Mavoglurant, aslo known as AFQ056, is an experimental drug candidate for the treatmen | ||||
17030611 | MMAF (Monomethyl auristatin F) | 745017-94-1 | 98% | |
Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of som | ||||
17030308 | Merimepodib | 198821-22-6 | 98% | |
Merimepodib, also known as VX-497, is orally bioavailable IMPDH inhibitor, which inhi | ||||
17030302 | ML-264 | 1550008-55-3 | 98% | |
ML-264 is a Krppel-like factor 5 (KLF5) inhibitor That Potently Inhibits Growth of Co | ||||
17030109 | MK-8245 | 1030612-90-8 | 98% | |
MK-8245 is a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and a | ||||
17030101 | MLN-1117 | 1268454-23-4 | 98% | |
Serabelisib (also known as MLN1117, INK1117, and TAK-117) is an orally bioavailable i | ||||
17022811 | ML-281 | 1404437-62-2 | 98% | |
ML-281 is a potent ans selective STK33 inhibitor (IC50 = 14 nM). ML281 showed low nan | ||||
17022804 | Maraviroc | 376348-65-1 | 98% | |
Maraviroc (UK-427857; Selzentry; Celsentri) is a selective CCR5 antagonist (IC50= 6.4 | ||||
17022403 | MMAE (Monomethyl auristatin E) | 474645-27-7 | 98% | |
MMAE, also known as Monomethyl auristatin E, is a synthetic antineoplastic agent. Bec | ||||
17021322 | Monastrol | 329689-23-8 | 98% | |
Monastrol is a cell-permeable small molecule inhibitor of kinesin-5(KIF11) which is | ||||
17021313 | MS049 | 1502816-23-0 | 98% | |
MS049 is a potent and selective inhibitor of PRMT4 and PRMT6 with IC50s of 34 nM | ||||
17021301 | Miransertib(ARQ 092) | 1313883-00-9 | 98% | |
ARQ 092 is a novel, orally bioavailable and selective AKT pathway inhibitor exhibit | ||||
712101 | MT-DADMe-ImmA(MTDIA HCl) | 1399840-35-7 | 98% | |
Methylthio-DADMe-immucillin-A (MT-DADMe-ImmA) is an 86-pm inhibitor of human 5-methyl | ||||
17011908 | 7-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-aMine | 7752-54-7 | 98% | |
7-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-aMine | ||||
17011107 | ML-7 | 110448-33-4 | 98% | |
ML-7 is an inhibitor of smooth muscle myosin light chain kinase (MLCK) with a Ki | ||||
17011105 | MX69 | 1005264-47-0 | 98% | |
MX69 is a MDM2/XIAP inhibitor, used for cancer treatment. |
Overnight Delivery
Fast & Safe Delivery Worldwide
Safety and Security
Intimate Service
Copyright 2015-2022 武汉永璨生物科技有限公司 版权所有 | 鄂ICP备17005301号-1